Locust Walk is a global investment bank that integrates corporate development strategy and execution with capital raising for innovative life science companies.

Locust Walk

Locust Walk is a global investment bank that integrates corporate development strategy and execution with capital raising for innovative life science companies.  

We support management and board members through all aspects of a deal – from clearly defining and assessing all options to developing company positioning and navigating through the full deal cycle from outreach to term sheet structuring to negotiating to close. 

Our suite of capabilities and data driven approach provides our clients with greater confidence on decision making, 
rapidly deployable full team, and seamless integration with our clients working as one global team.

For more information or to contact a deal team member, please visit www.locustwalk.com.

Locust Walk is excited to introduce three new members of our team! Welcome back Sophie Katz, Associate, joining from Harvard Business School and returning to the team after our summer ‘22 MBA internship program. Welcome to Sam Kessel MD, MBA, Associate, joining from LEK, and to John Blythe, Business Development Analyst, from Boston College. #EnjoyTheRide 
 
We are still growing! View our current openings: https://lnkd.in/d-_mg47 
 
Working at Locust Walk, you will be part of an extraordinary, diverse, and collaborative team. You will make a difference quickly and have a direct impact on our clients’ success. You will be challenged and given unparalleled opportunities for growth and development.

On this episode of Biotalk, Locust Walk’s podcast for biotech leaders, Geoff Meyerson shares our perspective on the Q2 Biopharma Market Conditions Report. A key takeaway from this episode is that companies should continue to focus on the factors they can control like building great companies which is a current financing challenge that is impacting how innovation is pursued. The unmet need is the ability of industry to meet that need and the FDA’s willingness to approve therapies. Eventually the macro economy will heal, companies need to do what they can to persist until then. 

Listen to Biotalk here: https://lnkd.in/eQd7c3WX 

Download the 2023 Q2 Biopharma Market Conditions Report:  https://lnkd.in/eNBRFWyR

We are thrilled to welcome Locust Walk's 2023 Analyst class! The Analysts will work with multiple clients simultaneously on strategy and analytics, strategic transactions, and capital markets projects. Welcome back Jeffrey Desloge from Boston College, Nancy Healy from Tufts University, and Isabelle Wilson from Dartmouth College, returning after Locust Walk’s summer ‘22 internship program, and a warm welcome Paige Fleming from Boston College.  #EnjoytheRide

The Q2 2023 #US biopharma landscape showed partners’ willingness to pay up for selected platform technologies, with an average licensing deal value of $705M this quarter which represented a 20% increase from the previous quarter. But M&A remained underwhelming, with an average deal size of $1.5B, less than half of the 3.9B completed in the first quarter. 

Download Locust Walk’s Q2 2023 Market Conditions report to learn more about the #US, #Europan, and #Asian biopharma landscapes: https://lnkd.in/eNBRFWyR

Each quarter, Locust Walk's deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Q2 Report applies the latest data to analyze current activities in the life sciences deal landscape.

Public markets have shown some signs of stabilization but IPO, private financing and strategic dealmaking still remain below historical levels with no evidence of a near-term reversal.
 
Click here to download the report: https://lnkd.in/eNBRFWyR
  
Next week, Locust Walk will release additional commentary on the present and future state of biopharma on our podcast Biotalk.  
 
 #biopharma #markettrends #lifesciences #global #deals #financing #strategictransactions

Locust Walk’s 2023 Regenerative Medicine Therapeutics Landscape Report outlines key development trends and transaction activity for iPSC and MSC therapeutics, characterized by a mix of licensing and M&A deals spread across a broad set of therapeutic areas. 

Licensing agreements spanning global territories garnered high deal values regardless of the therapeutic area of focus and stage of development. 

Download the report to learn more about the key strategic transactions and much more: https://lnkd.in/eKdz3tud

As a follow-up to Locust Walk's 2022 Regenerative Medicine Report and Stem Cell Tx Conference, we are pleased to share our 2023 Regenerative Medicine Therapeutics Landscape Report. In this report we review regenerative medicine MSC and iPSC technologies and discuss key companies, strategic transactions, and financings in this space.  

Click here to download the report: https://lnkd.in/eKdz3tud

Locust Walk is thrilled to welcome our 2023 Summer Interns. Throughout the next few months, they will work on various strategic transactions and strategy projects as well as analytics, and analyses of key trends across #biotech landscapes.

We welcome Summer MBA Associate, Austin Nadeau joining us from The Tuck School of Business at Dartmouth, and Summer Analysts Geoffrey Von Der Ahe, joining us from University of Southern California, Kavish Senthilkumar, joining us from University of Pennsylvania, and Kellen Kinsella and Thomas Policicchio, both joining us from Dartmouth College. 

#lifesciences #career #strategictransactions #lifesciencejobs #biotech #biopharma #capitalmarkets #businessdevlopment #dealteam #strategy

Locust Walk is pleased to present the third volume of the Deal Makers of Japan – exclusive interviews with Japan’s best dealmakers, featuring Shionogi Inc. This piece highlights how they are turning COVID complexity into opportunity and their long-term transformation strategy in response to the rapidly changing market. 

Click here to Deal Makers of Japan volume 3: https://lnkd.in/e6MhrPaG

Hiroshi Yamamoto of Locust Walk had the opportunity to sit down with Ms. Takuko Sawada, Vice Chairperson at Shionogi Inc., and discuss corporate strategy, operation, diversity and talent management, and R&D strategy.

Three seasoned RNA biotech CEOs joined Locust Walk’s Geoff Meyerson on a panel to discuss recent trends, lessons, and future directions of the transaction landscape for companies developing RNA therapeutics during our RNA Innovation Conference. The panel featured Josh Mandel-Brehm of CAMP4 Therapeutics, Jerry McMahon of STORM Therapeutics Limited, and Leslie J Williams of hC Bioscience, Inc.. The group discussed trends that have come forth as a function of current market conditions, such as the shift away from broad platform strategies towards asset-based, indication-specific drug development with a clear line of sight to the clinic. 

Click here to watch: https://lnkd.in/efRTXsac 

Following the keynote, the day consisted of 27 company presentations, 6 academic research presentations, and panel discussions showcasing cutting-edge science, industry trends, and high value opportunities in next generation RNA R&D. A replay is available for all registrants.  If you would like access to the presentations, please email events@locustwalk.com.

COM:LOCUSTWALK

Locust Walk

Analysis Not Available